Aspirin for Primary Prevention of Cardiovascular Events
Hesham K. Abdelaziz(University of North Dakota), Jawahar L. Mehta(University of Arkansas for Medical Sciences), David H. Roberts(University of Liverpool), Naga Venkata K. Pothineni(Central Arkansas Veterans Healthcare System), Herbert D. Aronow, Mohammed Saleh(Creighton University), Michael Megaly(St. John Medical Center), Marwan Saad(Ain Shams University), Rahul Potluri(Aston University), David Lai Chin Kon(University of Liverpool), J. Dawn Abbott(Brown University), Deepak L. Bhatt(Mount Sinai Hospital)
Cited by 140
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k
A Controlled Trial of Renal Denervation for Resistant Hypertension
|New England Journal of Medicine|2014|2.2k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k